Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis

A 65-year-old female with biopsy-confirmed nephrogenic systemic fibrosis (NSF) received a kidney transplantation. Despite good kidney function, her symptoms continued to progress. Deferoxamine was administered intramuscularly at 500 mg/day and later 1000 mg/day after 1 week with no adverse effects....

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Nelson, Pittelkow, Mark R., Lee, Christine U., Good, Jonathan A., Hanley, Matthew M., Moyer, Thomas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421246/
https://www.ncbi.nlm.nih.gov/pubmed/25984024
http://dx.doi.org/10.1093/ndtplus/sfp042
_version_ 1782369825265287168
author Leung, Nelson
Pittelkow, Mark R.
Lee, Christine U.
Good, Jonathan A.
Hanley, Matthew M.
Moyer, Thomas P.
author_facet Leung, Nelson
Pittelkow, Mark R.
Lee, Christine U.
Good, Jonathan A.
Hanley, Matthew M.
Moyer, Thomas P.
author_sort Leung, Nelson
collection PubMed
description A 65-year-old female with biopsy-confirmed nephrogenic systemic fibrosis (NSF) received a kidney transplantation. Despite good kidney function, her symptoms continued to progress. Deferoxamine was administered intramuscularly at 500 mg/day and later 1000 mg/day after 1 week with no adverse effects. Urine excretion of gadolinium increased from 6.0 μg/day to 11.6 μg/day and subsequently to 13.0 μg/day with 500 mg/day and 1000 mg/day of deferoxamine, respectively. Serum levels, however, remain unchanged from 1.7 ng/ml to 1.4 ng/ml. Although chelation therapy may have a role in the treatment of NSF, deferoxamine is too weak and a stronger chelator is needed.
format Online
Article
Text
id pubmed-4421246
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44212462015-05-15 Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis Leung, Nelson Pittelkow, Mark R. Lee, Christine U. Good, Jonathan A. Hanley, Matthew M. Moyer, Thomas P. NDT Plus Case Report A 65-year-old female with biopsy-confirmed nephrogenic systemic fibrosis (NSF) received a kidney transplantation. Despite good kidney function, her symptoms continued to progress. Deferoxamine was administered intramuscularly at 500 mg/day and later 1000 mg/day after 1 week with no adverse effects. Urine excretion of gadolinium increased from 6.0 μg/day to 11.6 μg/day and subsequently to 13.0 μg/day with 500 mg/day and 1000 mg/day of deferoxamine, respectively. Serum levels, however, remain unchanged from 1.7 ng/ml to 1.4 ng/ml. Although chelation therapy may have a role in the treatment of NSF, deferoxamine is too weak and a stronger chelator is needed. Oxford University Press 2009-08 2009-04-23 /pmc/articles/PMC4421246/ /pubmed/25984024 http://dx.doi.org/10.1093/ndtplus/sfp042 Text en © The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Leung, Nelson
Pittelkow, Mark R.
Lee, Christine U.
Good, Jonathan A.
Hanley, Matthew M.
Moyer, Thomas P.
Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
title Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
title_full Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
title_fullStr Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
title_full_unstemmed Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
title_short Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
title_sort chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421246/
https://www.ncbi.nlm.nih.gov/pubmed/25984024
http://dx.doi.org/10.1093/ndtplus/sfp042
work_keys_str_mv AT leungnelson chelationofgadoliniumwithdeferoxamineinapatientwithnephrogenicsystemicfibrosis
AT pittelkowmarkr chelationofgadoliniumwithdeferoxamineinapatientwithnephrogenicsystemicfibrosis
AT leechristineu chelationofgadoliniumwithdeferoxamineinapatientwithnephrogenicsystemicfibrosis
AT goodjonathana chelationofgadoliniumwithdeferoxamineinapatientwithnephrogenicsystemicfibrosis
AT hanleymatthewm chelationofgadoliniumwithdeferoxamineinapatientwithnephrogenicsystemicfibrosis
AT moyerthomasp chelationofgadoliniumwithdeferoxamineinapatientwithnephrogenicsystemicfibrosis

Ejemplares similares